Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder (TIs-GAD)
Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder: A Randomized Controlled Trial
This randomized controlled trial will use a three-arm, parallel-group design to evaluate the efficacy and safety of 5-Hz Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) in adults with generalized anxiety disorder (GAD). A total of 75 participants will be randomized in a 1:1:1 ratio to receive stimulation targeting the right bed nucleus of the stria terminalis (BNST), stimulation targeting the right amygdala, or sham stimulation. Participants will receive three 20-minute sessions per day, with 1-hour intervals between sessions, for 7 consecutive days (21 sessions in total). The primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA) total score from baseline to Week 1. Secondary and exploratory assessments will include clinical symptoms, intolerance of uncertainty and related cognitive characteristics, treatment tolerability, adverse events, and EEG and MRI measures. Follow-up assessments will be conducted at Week 1, Week 4, and Week 8 from baseline to assess the durability of clinical effects and safety.
調査の概要
状態
条件
詳細な説明
Generalized anxiety disorder (GAD) is characterized by persistent and excessive anxiety and worry. Intolerance of uncertainty is an important cognitive feature associated with pathological worry. The amygdala and bed nucleus of the stria terminalis (BNST) contribute to threat processing, with evidence suggesting differences in their responses to brief and sustained threats. Comparing interventions targeting these regions may help clarify their contributions to anxiety symptoms, intolerance of uncertainty, and persistent worry.
Temporal interference stimulation uses two kilohertz-frequency alternating currents with a small frequency difference to generate an amplitude-modulated electric field envelope at the difference frequency. This study will compare right BNST-targeted and right amygdala-targeted stimulation using a 5-Hz envelope, with sham stimulation as the control.
Individualized head models will be constructed from each participant's T1-weighted magnetic resonance images. Electric field modeling will guide scalp electrode placement for the assigned target. Stimulation intensity will be individually adjusted according to participant tolerability within a range of 1.5-3.5 mA per channel, expressed as zero-to-peak amplitude.
Electroencephalography and magnetic resonance imaging will be used to investigate changes in theta-band activity and functional connectivity within anxiety-related networks. Associations between these changes and improvements in clinical symptoms and cognitive measures will be examined to explore the neural mechanisms of stimulation at the two targets. Peripheral blood samples will be collected at baseline, Week 1, and Week 8 and stored for future exploratory biomarker analyses related to GAD and treatment response.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Yumeng Ju, PhD
- 電話番号:86+18100731091
- メール:yumeng.ju@csu.edu.cn
研究連絡先のバックアップ
- 名前:Xueting Li, PhD Candidate
- メール:2458261900@qq.com
研究場所
-
-
Fujian
-
Fuzhou、Fujian、中国
- 募集
- Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital
-
コンタクト:
- Xueting Li
- 電話番号:86+13956590989
- メール:2458261900@qq.com
-
-
Hunan
-
Changsha、Hunan、中国
- 募集
- Second Xiangya Hospital of Central South University
-
コンタクト:
- Hui Liang
- 電話番号:86+13876220412
- メール:1136293417@qq.com
-
Changsha、Hunan、中国
- まだ募集していません
- Brain Hospital of Hunan Province (Hunan Second People's Hospital)
-
コンタクト:
- Wenwen Ou
- 電話番号:86+15116200923
- メール:TIassistant701@163.com
-
-
Jiangsu
-
Yangzhou、Jiangsu、中国
- 募集
- Jiangsu Yangzhou Wutaishan Hospital
-
コンタクト:
- Jinrong Sun
- 電話番号:86+13813176637
- メール:1723487395@qq.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 18 to 55 years, inclusive, of any sex;
- Diagnosis of generalized anxiety disorder (GAD) according to DSM-5 criteria, assessed by trained researchers using the Structured Clinical Interview for DSM-5 (SCID), without psychotic features;
- Hamilton Anxiety Rating Scale (HAMA) total score of 14 or higher at screening;
- Has completed at least junior high school education and has sufficient hearing, reading, writing, and comprehension abilities to complete study assessments;
- Is willing and able to provide written informed consent and comply with study visits, treatment procedures, laboratory tests, and other study requirements.
Exclusion Criteria:
- Participants with a current or previous diagnosis of a major psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), such as schizophrenia spectrum and other psychotic disorders or bipolar and related disorders;
- Pregnancy or lactation;
- Neurologic disorders or serious systemic diseases (e.g., thyroid disease, lupus erythematosus, diabetes, hepatic or renal impairment, active infection, major trauma);
- History of significant head injury or coma;
- Received any standardized neuromodulation therapy targeting the nervous system within the past 6 months before enrollment, including but not limited to electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS);
- Suspected or confirmed history of alcohol or substance dependence;
- Current severe suicidal ideation or recent suicide attempt;
- Current participation in another clinical trial or recent use of prohibited psychotropic medications;
- Positive urine drug screening or abnormal thyroid function tests;
- Contraindications to magnetic resonance imaging (MRI) or electroencephalography (EEG);
- Inability to provide fully informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Right BNST-targeted TI-tACS
Participants will receive 5-Hz temporal interference stimulation targeting the right bed nucleus of the stria terminalis (BNST), for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz). Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz) |
|
実験的:Right Amygdala-targeted TI-tACS
Participants will receive 5-Hz temporal interference stimulation targeting the right amygdala, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz). Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz) |
|
偽コンパレータ:Sham TI-tACS
Participants will receive sham temporal interference stimulation, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline to Week 1
時間枠:Baseline and Week 1
|
Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to Week 1. |
Baseline and Week 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical Response Rate
時間枠:Week 1, Week 4, and Week 8
|
Clinical response will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical response is defined as a reduction of at least 50% in HAMA total score compared with baseline. |
Week 1, Week 4, and Week 8
|
|
Clinical Remission Rate
時間枠:Week 1, Week 4, and Week 8
|
Clinical remission will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical remission is defined as a HAMA total score of 7 or less at the corresponding assessment time point. |
Week 1, Week 4, and Week 8
|
|
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score
時間枠:Baseline, Week 1, Week 4, and Week 8
|
Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to each subsequent assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
時間枠:Baseline, Week 1, Week 4, and Week 8
|
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), a clinician-administered scale with a total score range of 0 to 52. Higher scores indicate greater depressive symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMD-17 total score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) Score
時間枠:Baseline, Week 1, Week 4, and Week 8
|
Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire with a total score range of 0 to 21. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in GAD-7 score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Intolerance of Uncertainty Scale (IUS) Score
時間枠:Baseline, Week 1, Week 4, and Week 8
|
Intolerance of uncertainty will be assessed using the Intolerance of Uncertainty Scale (IUS), a 27-item self-report questionnaire with a total score range of 27 to 135. Higher scores indicate greater intolerance of uncertainty, which represents a worse outcome. The outcome will be calculated as the change in IUS total score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Anxiety and Depression Visual Analogue Scale Scores
時間枠:Baseline, Day 1, Week 1, Week 4, and Week 8
|
Subjective anxiety and depression severity will be assessed using visual analogue scale ratings for anxiety and depression. Each visual analogue scale score ranges from 0 to 10, with higher scores indicating greater subjective symptom severity, which represents a worse outcome. The outcome will be calculated as the change in visual analogue scale scores from baseline to each post-baseline assessment time point |
Baseline, Day 1, Week 1, Week 4, and Week 8
|
|
Treatment-Emergent Side Effects During the Intervention and Follow-up Period
時間枠:Week 1, Week 4, and Week 8
|
Treatment-emergent side effects will be assessed using a physical treatment side-effect assessment that records the presence, type, severity, and relationship to the study intervention of adverse events. This outcome will be summarized as the occurrence and severity of treatment-emergent side effects during the intervention and follow-up period; higher severity indicates a worse safety outcome. |
Week 1, Week 4, and Week 8
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in EEG Theta-Band Power
時間枠:Baseline, Week 1, and Week 8
|
Brain electrophysiological activity will be assessed using electroencephalography (EEG). Theta-band power (4-8 Hz) will be assessed using EEG. The outcome will be calculated as the change in theta-band power from baseline to each post-baseline assessment. |
Baseline, Week 1, and Week 8
|
|
Change in Right Amygdala Seed-Based Resting-State Functional Connectivity
時間枠:Baseline, Week 1, and Week 8
|
Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right amygdala and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment. |
Baseline, Week 1, and Week 8
|
|
Change in Right BNST Seed-Based Resting-State Functional Connectivity
時間枠:Baseline, Week 1, and Week 8
|
Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right bed nucleus of the stria terminalis (BNST) and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment. |
Baseline, Week 1, and Week 8
|
|
Blinding Integrity at the End of Treatment
時間枠:Week 1
|
Blinding integrity will be assessed using a brief questionnaire completed independently by participants and outcome assessors after the week 1 primary outcome assessment. Respondents will indicate whether they believe the participant received active stimulation, sham stimulation, or "do not know." They will also be asked to guess the specific treatment assignment: right BNST-targeted stimulation, right amygdala-targeted stimulation, sham stimulation, or "do not know." The reasons for their guesses will be recorded. The percentages of correct guesses, incorrect guesses, and "do not know" responses will be summarized by randomized group, separately for participants and outcome assessors. Actual treatment assignments will not be disclosed during this assessment. |
Week 1
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディチェア:Yan Zhang, PhD、Second Xiangya Hospital of Central South University
- 主任研究者:Yumeng Ju, PhD、Second Xiangya Hospital of Central South University
- スタディディレクター:Jiawu Ji, PhD、Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- FZLL202651
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared because the dataset includes sensitive neuroimaging and biological data that may compromise participant confidentiality.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。